<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2016-10-20" updated="2019-12-02">
  <drugbank-id primary="true">DB12834</drugbank-id>
  <name>Secnidazole</name>
  <description>Secnidazole is a second-generation 5-nitroimidazole antimicrobial that is structurally related to other 5-nitroimidazoles including [DB00916] and [DB00911], but displays improved oral absorption and longer terminal elimination half-life than antimicrobial agents in this class [A27210]. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria and protozoa. In September 2017, FDA granted approval to secnidazole under the market name Solosec as a single-dose oral treatment for bacterial vaginosis, which is a common vaginal infection in women aged 15 to 44 years. The antimicrobial therapy is only intended to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria [FDA Label].</description>
  <cas-number>3366-95-8</cas-number>
  <unii>R3459K699K</unii>
  <average-mass>185.183</average-mass>
  <monoisotopic-mass>185.080041226</monoisotopic-mass>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A27210</ref-id>
        <pubmed-id>8706597</pubmed-id>
        <citation>Gillis JC, Wiseman LR: Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs. 1996 Apr;51(4):621-38.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated for the treatment of bacterial vaginosis in adult women . </indication>
  <pharmacodynamics>Secnidazole is a nitroimidazole antimicrobial drug that displays selectivity against many anaerobic Gram-positive and Gram-negative bacteria and protozoa [A27210]. In vitro studies demonstrates the effectiveness of the drug against *Bacteroides fragilis*, *Trichomonas vaginalis*, *Entamoeba histolytica* and *Giardia lamblia* [A27210]. There is no significant bacterial or protozoal resistance reported from secnidazole treatment [A27210]. </pharmacodynamics>
  <mechanism-of-action>Secnidazole enters the bacterial cell as a prodrug without an antimicrobial activity. The drug is converted to an active form via reduction of nitro groups to radical anions by bacterial enzymes. The radical anions are thought to interfere with bacterial DNA synthesis of susceptible isolates [FDA Label]. </mechanism-of-action>
  <toxicity>Oral LD50 in mouse, rabbit and rat is 300 mg/kg, 3200 mg/kg and 980 mg/kg, in a respective order [MSDS]. Secnidazole was positive in the Bacterial Reverse Mutation Assay, but was negative for the rat micronucleus test and mouse lymphoma test. No parental toxicity or signs of reproductive toxicity were observed in female rat fertility studies at doses of up to the maximum tolerated dose of 300 mg/kg/day [FDA Label]. </toxicity>
  <metabolism>According to *in vitro* studies, secnidazole is metabolized via oxidation by human hepatic CYP450 enzyme system with ≤ 1% conversion to metabolites [FDA Label].</metabolism>
  <absorption>Secnidazole is rapidly and completely absorbed after oral administration [A27210]. Following a single oral dose of 2 g in healthy adult female subjects, the mean (SD) secnidazole peak plasma concentration (Cmax) of 45.4 (7.64) mcg/mL and mean (SD) systemic exposure (AUC0-inf) of 1331.6 (230.16) mcg x hr/mL was reached. Median (range) time to peak concentration (Tmax) was 4.0 (3.0-4.0) hours [FDA Label]. </absorption>
  <half-life>The plasma elimination half-life for secnidazole is approximately 17 hours [FDA Label]. </half-life>
  <protein-binding>The plasma protein binding of secnidazole is &lt; 5-15% [FDA Label, A27210]. </protein-binding>
  <route-of-elimination>The predominant route of elimination is renal elimination. Following a single oral dose of 2g secnidazole, approximately 15% of the drug is excreted as unchanged compoung in the urine [FDA Label]. </route-of-elimination>
  <volume-of-distribution>The apparent volume of distribution of secnidazole is approximately 42-49 L [FDA Label, A27210].</volume-of-distribution>
  <clearance>The total body clearance of secnidazole is approximately 25 mL/min. The renal clearance of secnidazole is approximately 3.9 mL/min [FDA Label]. </clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as nitroimidazoles. These are compounds containing an imidazole ring which bears a nitro group.</description>
    <direct-parent>Nitroimidazoles</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Azoles</class>
    <subclass>Imidazoles</subclass>
    <alternative-parent>1,2,5-trisubstituted imidazoles</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>N-substituted imidazoles</alternative-parent>
    <alternative-parent>Nitroaromatic compounds</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic oxoazanium compounds</alternative-parent>
    <alternative-parent>Organic zwitterions</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <substituent>1,2,5-trisubstituted-imidazole</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Allyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>C-nitro compound</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>N-substituted imidazole</substituent>
    <substituent>Nitroaromatic compound</substituent>
    <substituent>Nitroimidazole</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitro compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxoazanium</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic zwitterion</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Trisubstituted imidazole</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">1-(2­ hydroxypropyl)-2-methyl-5-nitroimidazole</synonym>
    <synonym language="english" coder="">1-(2-methyl-5-nitro-1H-imidazol-1-yl) propan-2­ ol</synonym>
    <synonym language="english" coder="inn/usan">Secnidazole</synonym>
  </synonyms>
  <products>
    <product>
      <name>Solosec</name>
      <labeller>Lupin Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>27437-051</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Granule</dosage-form>
      <strength>2 g/4.8g</strength>
      <route>Oral</route>
      <fda-application-number>NDA209363</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solosec</name>
      <labeller>Ropack Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>64811-401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Granule</dosage-form>
      <strength>2 g/4.8g</strength>
      <route>Oral</route>
      <fda-application-number>NDA209363</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Solosec</name>
      <labeller>Symbiomix Therapeutics</labeller>
      <ndc-id/>
      <ndc-product-code>71000-102</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-09-29</started-marketing-on>
      <ended-marketing-on>2017-10-30</ended-marketing-on>
      <dosage-form>Granule</dosage-form>
      <strength>2 g/4.8g</strength>
      <route>Oral</route>
      <fda-application-number>NDA209363</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Solosec</name>
      <ingredients>Secnidazole</ingredients>
    </mixture>
    <mixture>
      <name>Solosec</name>
      <ingredients>Secnidazole</ingredients>
    </mixture>
    <mixture>
      <name>Solosec</name>
      <ingredients>Secnidazole</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antibacterials for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiinfectives for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiparasitic Agents</category>
      <mesh-id>D000977</mesh-id>
    </category>
    <category>
      <category>Antiparasitic Products, Insecticides and Repellents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiprotozoals</category>
      <mesh-id>D000981</mesh-id>
    </category>
    <category>
      <category>Imidazoles</category>
      <mesh-id>D007093</mesh-id>
    </category>
    <category>
      <category>Nitro Compounds</category>
      <mesh-id>D009574</mesh-id>
    </category>
    <category>
      <category>Nitroimidazole Antimicrobial</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nitroimidazole Derivatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nitroimidazoles</category>
      <mesh-id>D009593</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Trichomonas vaginalis, Giardia duodenalis, and Entamoeba histolytica</affected-organism>
    <affected-organism>Bacteria and protozoa</affected-organism>
    <affected-organism>Bacteroides fragilis</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Granule</form>
      <route>Oral</route>
      <strength>2 g/4.8g</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="P01AB07">
      <level code="P01AB">Nitroimidazole derivatives</level>
      <level code="P01A">AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES</level>
      <level code="P01">ANTIPROTOZOALS</level>
      <level code="P">ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS</level>
    </atc-code>
    <atc-code code="J01RA07">
      <level code="J01RA">Combinations of antibacterials</level>
      <level code="J01R">COMBINATIONS OF ANTIBACTERIALS</level>
      <level code="J01">ANTIBACTERIALS FOR SYSTEMIC USE</level>
      <level code="J">ANTIINFECTIVES FOR SYSTEMIC USE</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB12834.pdf?1505839374</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB12834.pdf?1505840614</msds>
  <patents>
    <patent>
      <number>10335390</number>
      <country>United States</country>
      <approved>2019-07-02</approved>
      <expires>2035-09-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.25</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>4.88e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-0.043</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>1-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>secnidazole</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>185.183</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>185.080041226</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC(O)CN1C(C)=NC=C1N(=O)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C7H11N3O3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>KPQZUUQMTUIKBP-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>83.87</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>45.64</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>17.57</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>15.16</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>3.08</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>94433</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>71815</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347829000</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>64839</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50349330</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Secnidazole</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL498847</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>